The Journey to Kona The Journey to Kona: Inspired by BethAnn Telford
Find Us On:
Athletes: Login to Fundraise
Forgot Password

Our Mission and Focus:

To invest in research aimed at finding the fastest possible route to a cure.

We believe that a nimble, focused and aggressive entrepreneurial model will increase the number of therapies discovered and then enable those therapies to be more rapidly driven into the clinic. We provide researchers with the pivotal support they need to make critical breakthroughs. We fund novel translational research aimed at finding the fastest possible route to a cure.

Our partners range from medical research centers to early-stage biotechnology companies to large multi-national pharmaceutical companies. These partners all share a vision of driving translational research and moving treatments as fast as possible from basic discovery to the clinic.

Since brain cancer affects a relatively small portion of the population, we recognize the importance of investing in the early stages of the most novel sectors of the discovery and development pipeline in order to “buy down the risk” for our partners and speed progress of innovative new treatments to the clinic.

Brain Tumor Facts

More than 200,000 people in the United States will be diagnosed with a primary or metastatic brain tumor over the next twelve months.

Brain tumors…

    * are the leading cause of cancer death among children and young adults.
    * cannot be prevented because their causes are currently unknown.
    * require increased public awareness & research funding if we hope to end this devastating disease.

Our Impact

Since its founding in 2001 by Steve and Dan Case, ABC² has provided more than $16 million in research funding to highly qualified research investigators and physician-scientists from 42 institutions.

In 2009, ABC² played a key role in convincing The National Cancer Institute to study Glioblastoma multiforme (GBM), the most common and most aggressive type of brain tumor, as the first cancer to be analyzed for the Cancer Genome Atlas.

To learn more, go to